Stay updated with breaking news from Nasdaq Cbay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) has been given an average rating of “Buy” by the nine analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. […]
StockNews.com upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) from a sell rating to a hold rating in a research report report published on Tuesday morning. A number of other brokerages have also weighed in on CBAY. HC Wainwright raised their target price on shares of CymaBay Therapeutics from $10.00 to $12.00 in a […]
StockNews.com upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) from a sell rating to a hold rating in a report issued on Tuesday morning. Several other brokerages have also issued reports on CBAY. Cantor Fitzgerald upped their price target on CymaBay Therapeutics from $13.00 to $15.00 in a research note on Tuesday, May 16th. […]
StockNews.com upgraded shares of CymaBay Therapeutics (NASDAQ:CBAY – Get Rating) from a sell rating to a hold rating in a research note published on Tuesday morning. CBAY has been the topic of several other reports. Piper Sandler boosted their target price on shares of CymaBay Therapeutics from $12.00 to $19.00 and gave the company an […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating)’s share price dropped 4.6% on Monday after an insider sold shares in the company. The company traded as low as $8.68 and last traded at $8.69. Approximately 786,486 shares traded hands during trading, a decline of 52% from the average daily volume of 1,639,025 shares. The stock had […]